The Effect of Intravenous Autologous Activated Platelet-Rich Plasma Therapy on “Profibrotic Cytokine” IL-1<i>β</i> Levels in Severe and Critical COVID-19 Patients: A Preliminary Study

<div>Severe and critical patients’ plasma IL-1<i>β</i> profile.</div>

Scientifica

fig1

Figure 1

Figure 1: The Effect of Intravenous Autologous Activated Platelet-Rich Plasma Therapy on “Profibrotic Cytokine” IL-1<i>β</i> Levels in Severe and Critical COVID-19 Patients: A Preliminary Study 

Figure 1 | The Effect of Intravenous Autologous Activated Platelet-Rich Plasma Therapy on “Profibrotic Cytokine” IL-1β Levels in Severe and Critical COVID-19 Patients: A Preliminary Study 